Enanta Pharmaceuticals, Inc (ENTA) Stock Price

ENTAStock

$11.10−2.46%52W

Market Cap$323.29M

P/E—

PEG Ratio—

Div yield—

Beta0.73

ENTA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-34.03%

Price vs S&P 500 (4W)-7.02%

VGM Score41.05

Book Value / Share (Quarterly)$3.47

P/TBV (Annual)0.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.83%

Cash Flow / Share (Quarterly)$-1.27

Price vs S&P 500 (YTD)-41.54%

Net Profit Margin (TTM)-96.89%

EPS (TTM)$-2.41

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$-2.41

Revenue Growth (5Y)-11.82%

EPS (Annual)$-3.84

ROI (Annual)-39.39%

Net Profit Margin (5Y Avg)-137.71%

Cash / Share (Quarterly)$6.51

Revenue Growth QoQ (YoY)-21.60%

ROA (Last FY)-29.17%

Revenue Growth TTM (YoY)0.70%

EBITD / Share (TTM)$-1.99

ROE (5Y Avg)-67.21%

Operating Margin (TTM)-89.99%

Cash Flow / Share (Annual)$-1.50

P/B Ratio3.20x

P/B Ratio (Quarterly)4.19x

Net Income / Employee (Annual)$-682,400

EV / Revenue (TTM)6.38x

Net Interest Coverage (TTM)12.65x

ROA (TTM)-20.70%

EV / EBITDA (TTM)28.16x

EPS Incl Extra (Annual)$-3.84

Current Ratio (Annual)4.21x

Quick Ratio (Quarterly)3.62x

3-Month Avg Trading Volume0.23M

52-Week Price Return-2.46%

Revenue / Employee (TTM)$543,800

Tangible BV / Share (Quarterly)$10.29

P/S Ratio (Annual)4.95x

Asset Turnover (Annual)0.23x

52-Week High$17.15

Operating Margin (5Y Avg)-148.06%

EPS Excl Extra (Annual)$-3.84

CapEx CAGR (5Y)54.82%

Tangible BV CAGR (5Y)-11.25%

26-Week Price Return-24.13%

Quick Ratio (Annual)4.03x

13-Week Price Return-19.21%

Total Debt / Equity (Annual)2.21x

Current Ratio (Quarterly)3.76x

Enterprise Value$416.26M

Revenue / Share Growth (5Y)-13.04%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-33.15%

Revenue / Employee (Annual)$544,400

Pretax Margin (Annual)-127.90%

Cash / Share (Annual)$8.83

3-Month Return Std Dev44.43%

Net Income / Employee (TTM)$-526,900

ROE (Last FY)-126.53%

Net Interest Coverage (Annual)-13.33x

EPS Basic Excl Extra (Annual)$-3.84

P/FCF (TTM)18.63x

Receivables Turnover (TTM)8.78x

Total Debt / Equity (Quarterly)1.25x

EPS Incl Extra (TTM)$-2.41

Receivables Turnover (Annual)9.66x

ROI (TTM)-26.77%

P/S Ratio (TTM)4.95x

Pretax Margin (5Y Avg)-144.00%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$10.29

Price vs S&P 500 (52W)-17.99%

Year-to-Date Return-29.61%

5-Day Price Return-9.76%

EPS Normalized (Annual)$-3.84

ROA (5Y Avg)-27.87%

Net Profit Margin (Annual)-125.36%

Month-to-Date Return-15.78%

Cash Flow / Share (TTM)$-6.26

EBITD / Share (Annual)$-3.79

Operating Margin (Annual)-130.65%

LT Debt / Equity (Annual)1.74x

ROI (5Y Avg)-39.39%

LT Debt / Equity (Quarterly)0.89x

EPS Basic Excl Extra (TTM)$-2.41

P/TBV (Quarterly)0.97x

P/B Ratio (Annual)3.95x

Pretax Margin (TTM)-96.74%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-21.90%

Beta0.73x

P/FCF (Annual)57.32x

Revenue / Share (TTM)$2.24

ROE (TTM)-61.84%

52-Week Low$10.20

vGradeC

gGradeD

mGradeC

vgmGradeC

ENTA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.54	-$0.67	-25.23%(-$0.14)
Q1 2026	May 11, 2026	-$0.57	-$0.45	+20.82%(+$0.12)
Q4 2025	Feb 9, 2026	-$0.80	-$0.42	+47.76%(+$0.38)
Q3 2025	Nov 17, 2025	-$1.01	-$0.87	+13.86%(+$0.14)
Q2 2025	Aug 11, 2025	-$0.89	-$0.85	+3.95%(+$0.04)

ENTA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.15

4.25

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ENTAEnanta Pharmaceuticals, Inc	C	D	C	5.0x	0.7%	—	—	$11.10
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals is a biotechnology company specializing in small-molecule drug discovery for virology and immunology. Its pipeline includes candidates for RSV, SARS-CoV-2, hepatitis B, and type 2 inflammatory disease. The company generates revenue primarily through royalties, including from its collaboration with AbbVie.

ENTA Next Earnings Report

Report dateNov 16, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.77

Revenue estimate$15.72M

Also reporting on Nov 16, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

FENCFennec Pharmaceuticals Inc. Common StockBiological Products
CCCCC4 Therapeutics, Inc.Biological Products
ASPIASP Isotopes Inc. Common StockIndustrial Chemicals
NLNLI Holdings, Inc.Industrial Chemicals
CGCCanopy Growth Corporation Common SharesPharmaceutical Preparations
SNDLSundial Growers Inc. Common SharesPharmaceutical Preparations
OECOrion S.A.Industrial Chemicals
GLASGlass House Brands Inc.Pharmaceutical Preparations

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$10.20

High$17.15